telmisartan / Generic mfg. - LARVOL DELTA

BEYOND DIABETES: WHEN NEPHROTIC SYNDROME IS NOT DIABETIC NEPHROPATHY IN A PATIENT WITH LONG STANDING TYPE TWO DIABETES MELLITUS (ISN-WCN 2026) - "Her medications included biphasic human insulin 20 units in the morning and 12 units at night, empagliflozin 10mg daily, vildagliptin/metformin 50/500 once daily, telmisartan 40 mg once daily, and atorvastatin 80 mg at night .Glycemic control was sub-optimal (HbA1c 7.8%) and fundoscopy revealed no evidence of diabetic or hypertensive retinopathy.She reported intermittent joint pains without arthritis or constitutional symptoms.On examination, she was hemodynamically stable with bilateral pedal edema...There was no evidence of diabetic nephropathy, confirming primary membranous nephropathy.The patient was initiated on the modified Ponticelli regimen, consisting of oral corticosteroids alternating with oral cyclophosphamide...A high index of suspicion, serologic workup, and renal biopsy helped uncover primary membranous nephropathy in a diabetic patient, allowing timely immunosuppressive therapy with promising early response. Clinicians should, therefore, maintain..."

Clinical • Cardiovascular • Chronic Kidney Disease • Diabetes • Diabetic Nephropathy • Diabetic Retinopathy • Glomerulonephritis • Hypertension • Immunology • Metabolic Disorders • Musculoskeletal Diseases • Musculoskeletal Pain • Nephrology • Orthopedics • Renal Disease • Retinal Disorders • Type 2 Diabetes Mellitus

SGLT- 2I: "CAN BE A HOPE FOR PERITONEAL DIALYSIS PATIENTS." (ISN-WCN 2026) - "At baseline, his blood pressure was 168/88 mmHg with telmisartan 80 mg/day, amlodipine 10 mg /day, prazosin 10 mg/day, and torsemide 100 mg/day. Other medications were dapagliflozin 10mg/day, linagliptin 5 mg/day, sodium bicarbonate 1000 mg twice daily, insulin, atorvastatin 10mg/day, and aspirin 75 mg/day...There was no hospitalization in this follow-up period.Conclusion As the drug is well tolerated and no adverse effects are noted in this 35-month follow-up, we may hope to use this drug in some dialysis-dependent patients. The findings in this case report need to be confirmed in a large prospective study with a longer follow-up period."

Clinical • Cardiovascular • Chronic Kidney Disease • Diabetes • Diabetic Nephropathy • Hypertension • Metabolic Disorders • Nephrology • Renal Disease • Type 2 Diabetes Mellitus

TIRZEPATIDE FOR RESISTANT HYPERTENSION IN NON-DIABETIC IGA NEPHROPATHY (ISN-WCN 2026) - "SGLT2 inhibitors and spironolactone were previously discontinued due to recurrent balanoposthitis and hyperkalemia...BP normalized dramatically (200/100→118/70 mmHg, 82/30 mmHg reduction), achieving KDIGO targets and enabling 50% medication reduction (6→3 drugs: discontinued minoxidil, prazosin, clonidine; continued telmisartan, chlorthalidone, cilnidipine)...This represents a paradigm shift toward metabolic intervention in proteinuric non-diabetic CKD with obesity and resistant hypertension. GLP-1 receptor agonists merit investigation as cornerstone therapies alongside RAAS inhibitors and SGLT2 inhibitors, particularly in advanced fibrosis where immunosuppression risks may outweigh benefits."

Cardiovascular • Chronic Kidney Disease • Diabetic Nephropathy • Fibrosis • Genetic Disorders • Glomerulonephritis • Hypertension • IgA Nephropathy • Immunology • Lupus Nephritis • Obesity • Renal Disease

FINERENONE IN PROTEINURIA MANAGEMENT AMONG DIABETIC KIDNEY DISEASE PATIENTS: REAL-WORLD DATA FROM CENTRAL INDIA (ISN-WCN 2026) - "Four(6.15%) patients had developed hyperkalemia ( ≥5.5mEq/L).Conclusion In this prospective observational study, finerenone demonstrated a favourable safety profile and variable efficacy in reducing albuminuria among patients with diabetic kidney disease already receiving maximum tolerated doses of dapagliflozin and telmisartan.A gradient effect was observed, with patients exhibiting higher baseline UACR achieving greater reductions in proteinuria. However, the observed heterogeneity in response highlights the need for personalized therapeutic approaches and biomarker-based patient selection. Larger, controlled studies are warranted to validate these results and optimize the clinical use of finerenone in diverse diabetic kidney disease population patients."

Clinical • Real-world • Real-world evidence • Cardiovascular • Chronic Kidney Disease • Diabetes • Diabetic Nephropathy • Fibrosis • Immunology • Inflammation • Metabolic Disorders • Nephrology • Renal Disease • Type 2 Diabetes Mellitus

B-OXIDATION AND GLUCOSE METABOLISM IN THE MITOPHAGY-MEDIATED MITOCHONDRIAL QUALITY CONTROL MECHANISM IN THE RENAL CORTEX DURING THE NORMOALBUMINURIC STAGE OF DIABETES MELLITUS (ISN-WCN 2026) - "The objective of this research is to investigate fatty acids related to β-oxidation, which is responsible for energy production in mitochondria, the dynamics of carnitine that transports these fatty acids, and glucose metabolism in the renal cortex.Methods Four groups of rats (n=5 per group) received one of the following treatments: 1) streptozotocin (STZ) group: rats with DM induced by STZ injection (STZ, 65 mg/kg, i.v.); 2) Sham group: rats receiving the STZ vehicle; 3) STZ+TLM group: STZ rats treated with telmisartan (TLM, an angiotensin receptor blocker; 10 mg/kg/day in chow); and 4) Sham+TLM group: TLM-treated Sham rats...p62, BNIP3, CPT2, ACADVL, and HK2 did not differ among groups.Conclusion In the renal cortex, DM-induced mitophagy was associated with a metabolic shift from ω-6 to ω-3 fatty acids, increased acylcarnitine levels, enhanced β-oxidation, and gluconeogenesis. These were blunted by the antioxidant effects of TLM, suggesting that they may be closely..."

Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus • ACADVL

SYNERGISTIC RENOPROTECTION WITH FINERENONE, DAPAGLIFLOZIN, AND TELMISARTAN IN DIABETIC KIDNEY DISEASE: REAL-WORLD EVIDENCE FROM SOUTH ASIA (ISN-WCN 2026) - "No hospitalisations or deaths were reported during follow-up.Conclusion In patients with DKD already receiving maximally tolerated dapagliflozin and telmisartan, the addition of finerenone resulted in substantial proteinuria reduction and renal stability without increased adverse events. These findings highlight the complementary renoprotective mechanisms and safety of combined SGLT2–MRA–RAAS blockade in real-world South Asian practice."

Clinical • HEOR • Real-world • Real-world evidence • Chronic Kidney Disease • Diabetes • Diabetic Nephropathy • Hypotension • Infectious Disease • Metabolic Disorders • Nephrology • Renal Disease • Type 2 Diabetes Mellitus

RECURRENT PARALYTIC ILEUS ASSOCIATED WITH TIRZEPATIDE ADMINISTRATION IN A 72-YEAR-OLD MALE AFTER ROBOT-ASSISTED RADICAL CYSTECTOMY WITH ILEAL CONDUIT CONSTRUCTION (ISN-WCN 2026) - "Two and a half years earlier, he was diagnosed with low-grade papillary urothelial carcinoma with early invasion and underwent five transurethral resections of bladder tumor (TUR-Bt) over 1.5 years.His medications included rosuvastatin, hydrochlorothiazide, eplerenone 50 mg, telmisartan 80 mg, amlodipine 5 mg, and glucose-lowering agents: dapagliflozin 10 mg, glimepiride, sitagliptin 50 mg, insulin glargine, and insulin human R. One week before surgery, insulin and oral glucose-lowering agents were replaced with tirzepatide 2.5 mg weekly...Chronic kidney disease alters drug pharmacokinetics and intestinal sensitivity [5], potentially amplifying GLP-1RA/GIP effects. These factors highlight the need for preventive measures against postoperative adhesions and electrolyte disturbances with acidosis."

Bladder Cancer • Cardiovascular • Chronic Kidney Disease • Diabetes • Diabetic Nephropathy • Hypertension • Metabolic Disorders • Nephrology • Renal Disease • Solid Tumor • Type 2 Diabetes Mellitus • Urology • Urothelial Cancer

The effect of medical therapies for subthreshold abdominal aortic aneurysm growth and mortality: a network meta-analysis of randomized controlled trials. (PubMed, Interdiscip Cardiovasc Thorac Surg) - "Current evidence highlights ongoing uncertainty regarding the efficacy of medical therapies in reducing subthreshold AAA growth rates, rates of referral for surgical repair, or overall mortality. The absence of statistically significant benefit may reflect underpowered datasets rather than definitive treatment inefficacy. Future large-scale, appropriately powered randomized controlled trials evaluating emerging medical treatments are required to accurately assess their clinical potential."

Journal • Retrospective data • Cardiovascular

High-performance thin-layer chromatographic method for simultaneous determination of some Angiotensin II Receptor Antagonists with amlodipine in spiked human plasma with UV detection. (PubMed, BMC Chem) - "A simple, sensitive, precise, and cost-effective high-performance thin-layer chromatographic method has been developed and validated for the simultaneous determination of Amlodipine and some Angiotensin II Receptor Antagonist drugs, including Olmesartan, Telmisartan, Candesartan, Losartan, and Irbesartan, in spiked human plasma. Amlodipine and the investigated Angiotensin II Receptor Antagonist drugs were successfully detected and quantified in both bulk drug and plasma samples, yielding high recovery percentages and low standard deviation values. The greenness of the proposed HPTLC method has been evaluated using the standards of greenness profile (AGREE and GAPI) and Eco-Scale."

Journal

Low-dose telmisartan protects against myocardial ischemia/reperfusion injury via dual mechanisms: AMPK activation and AMPK-independent calcium homeostasis. (PubMed, Int J Cardiol) - "Low-dose Telmisartan confers cardioprotection against I/R injury via dual mechanisms: it primarily utilizes AMPK-dependent signaling to combat oxidative stress, apoptosis, and infarction, while independently of AMPK, it preserves calcium homeostasis and activates LKB1."

IO biomarker • Journal • Cardiovascular • Myocardial Ischemia • Reperfusion Injury • BCL2 • STK11

One health considerations in veterinary palliative medicine. (PubMed, Vet Anim Sci) - "Environmental challenges include the persistence of barbiturates, NSAIDs, antibiotics, chemotherapeutics, and telmisartan in the environment, and the consequences of after-care decisions such as home burial or cremation...The paper concludes with recommendations for responsible drug use, owner-centered communication, environmental safeguards for after-care, and the development of biodegradable euthanasia agents. A One Health approach ensures that compassionate animal care promotes human resilience and ecological stewardship."

Journal • Review

Astaxanthin, meclizine, mitoglitazone, pioglitazone, alpha-ketoglutarate, mifepristone, methotrexate, and atorvastatin-telmisartan do not increase lifespan in UM-HET3 mice. (PubMed, Geroscience) - "This study underscores the importance of rigorous, multi-site testing and highlights the challenges of translating promising initial findings into consistent lifespan benefits at other doses or with alternate starting ages. These results suggest that timing and dosage are critical variables in aging intervention studies and reinforce the need for cautious interpretation of single-site or single-cohort findings."

Journal • Preclinical

CARDIOVASCULAR BENEFITS OF TELMISARTAN IN METABOLIC DYSFUNCTION ASSOCIATED STEATOTIC LIVER DISEASE (ACC 2026) - "Telmisartan use was associated with significantly lower risks of multiple cardiovascular outcomes in MASLD. These findings highlight its potential to reduce cardiovascular complications, a major driver of morbidity and mortality in this population."

Cardiovascular • Congestive Heart Failure • Coronary Artery Disease • Heart Failure • Hepatology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease • PPARG

Hypertension Management Beyond Blood Pressure Control in India: An Expert Consensus on Angiotensin II Receptor Blocker and Calcium Channel Blocker Combination Therapy With Reference to Telmisartan and Cilnidipine. (PubMed, Cureus) - "Available evidence suggests that cilnidipine and telmisartan may offer potential benefits beyond BP reduction, largely based on pharmacologic properties and surrogate outcomes. Future large-scale, randomized, comparative outcome trials are needed to better define the relative clinical benefits of this combination."

Journal • Review • Cardiovascular • Chronic Kidney Disease • Diabetes • Hypertension • Metabolic Disorders • Nephrology • Renal Disease • Tobacco Cessation • Type 2 Diabetes Mellitus

Targeting PGAM5-driven mitochondrial integrated stress response slows ALS progression across subtypes. (PubMed, Neuron) - "The disruption of PGAM5-OMA1 interaction by a selective inhibitor (TAT-PO1) or pharmacological inhibition of PGAM5 with telmisartan suppresses mtISR activation and ameliorates ALS-related phenotypes by reshaping mtISR outputs in a manner distinct from those elicited by activation of translation initiation factor 2B (eIF2B). These findings establish PGAM5 as a convergent and actionable therapeutic target across ALS subtypes."

Journal • Amyotrophic Lateral Sclerosis • CNS Disorders • EIF2B4

REMAP-CAP: Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (clinicaltrials.gov) - P3 | N=10000 | Recruiting | Sponsor: UMC Utrecht | Phase classification: P4 ➔ P3 | N=7100 ➔ 10000 | Trial completion date: Dec 2023 ➔ Dec 2025 | Trial primary completion date: Dec 2021 ➔ Dec 2023

Enrollment change • Phase classification • Trial completion date • Trial primary completion date • Infectious Disease • Influenza • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases

REMAP-CAP: Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (clinicaltrials.gov) - P4 | N=6800 | Recruiting | Sponsor: MJM Bonten | N=4000 ➔ 6800 | Trial completion date: Feb 2019 ➔ Jun 2022 | Trial primary completion date: Feb 2019 ➔ Dec 2021 | Initiation date: Dec 2015 ➔ Apr 2016

Enrollment change • Trial completion date • Trial initiation date • Trial primary completion date • Infectious Disease • Influenza • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases

REMAP-CAP: Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (clinicaltrials.gov) - P4 | N=7100 | Recruiting | Sponsor: MJM Bonten | Trial completion date: Jun 2022 ➔ Dec 2023

Trial completion date • Infectious Disease • Influenza • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases

REMAP-CAP: Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (clinicaltrials.gov) - P4 | N=4000 | Recruiting | Sponsor: UMC Utrecht

New P4 trial • Infectious Disease • Influenza • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases

REMAP-CAP: Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (clinicaltrials.gov) - P3 | N=10000 | Recruiting | Sponsor: UMC Utrecht | Trial completion date: Dec 2025 ➔ Feb 2028 | Trial primary completion date: Dec 2023 ➔ Feb 2026

Trial completion date • Trial primary completion date • Infectious Disease • Influenza • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases

REMAP-CAP: Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (clinicaltrials.gov) - P3 | N=20000 | Recruiting | Sponsor: UMC Utrecht | N=10000 ➔ 20000

Enrollment change • Infectious Disease • Influenza • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases

Targeting AT1 receptors with telmisartan protects SH-SY5Y cells from 6-OHDA induced Parkinsonian neurotoxicity. (PubMed, Sci Rep) - No abstract available

Journal • CNS Disorders • Movement Disorders • Parkinson's Disease

COST OF HYPERTENSION MANAGEMENT AMONG PEOPLE LIVING WITH HYPERTENSION IN SELECTED PUBLIC HOSPITALS IN ILORIN, NIGERIA (ISPOR 2026) - "Anti-hypertensives used by 34.3%, 31.3% and 15.7% of PLHT were amilodipine, amilodipine/telmisartan, and amilodipine/termisartan/hydroclorthiazide respectively... Enrollment of PLHT in HISs was low. Direct medical cost had highest component of the total cost of illness. This study recommends that PLHT should be enrolled in HISs."

Clinical • Cardiovascular • Hypertension

Effect of Morning versus Bedtime Telmisartan on Ambulatory Blood Pressure and Exercise Response in Diabetic Hypertensive Patients: A Randomised Cross-over Trial. (PubMed, Niger Postgrad Med J) - "Bedtime telmisartan dosage improves nocturnal BP control, but morning dosage more successfully lowers exercise-induced BP spikes. Individualised chronotherapy may improve outcomes and control hypertension in diabetic patients."

Journal • Cardiovascular • Diabetes • Hypertension • Metabolic Disorders

Atypical Presentation of Balint Syndrome in a Patient with Right-sided Occipital-temporal Infarcts: A Case Report (AAN 2026) - "The patient received intravenous thrombolysis, along with edaravone 30mg twice daily for 14 days for neuroprotection, followed by secondary prevention with dual antiplatelet therapy, atorvastatin, amlodipine, and telmisartan. This case illustrates that unilateral right occipito-temporal lesions may give rise to the characteristic triad of Balint's syndrome. Progressive forms are often linked to degenerative disease; sudden-onset cases usually follow stroke, as in this patient. Recognition of such atypical presentations is crucial for timely diagnosis and targeted rehabilitation."

Case report • Clinical • Ataxia • Cardiovascular • CNS Disorders • Hematological Disorders • Ischemic stroke • Movement Disorders • Psychosomatic Disorders